Metronomic chemotherapy: An antiangiogenic scheduling

Clinical and Translational Oncology

Volumn 9, Issue 2, 2007, Pages 93-98

  Laquente, B ^a   Vinals F ^a,b   Germa J R ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antiangiogenic therapy; Metronomic chemotherapy; Tumoral angiogenesis

Indexed keywords

ANGIOPOIETIN; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IMATINIB; INTERLEUKIN 8; LETROZOLE; METHOTREXATE; MITOMYCIN C; MONOCLONAL ANTIBODY DC101; PACLITAXEL; PLACENTAL GROWTH FACTOR; ROFECOXIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; TREOSULFAN; UFT; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB; VINBLASTINE; VINCRISTINE; ANGIOGENESIS INHIBITOR;

ABSENCE OF SIDE EFFECTS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTIBIOTIC RESISTANCE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; METRONOMIC CHEMOTHERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NONHUMAN; OPTIMAL DRUG DOSE; PROSTATE CANCER; REVIEW; SURVIVAL RATE; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; DRUG ADMINISTRATION; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 34347204528     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0018-3     Document Type: Review

References (53)

1. Folkman J, Ingber D (1992) Inhibition of angiogenesis. Semin Cancer Biol 3:89-96
2. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
3. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410
4. Carmeliet P, Dor Y, Herbert JM et al (1998) Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485-490
5. Relf M, LeJeune S, Scott PA et al (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969
6. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186
7. Yancopoulos GD, Davis S, Gale NW et al (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242-248
8. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676
9. Ferrara N (2004) Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25:581-611
10. Albers P, Siener R, Krege S et al for the German Testicular Cancer Group (GTCSG) and Association of Urologic Oncology (AUO) of the German Cancer Society (2006) One course of adjuvant PEB chemotherapy versus retroperitoneal lymph node dissection in patients with stage I non seminomatous germ-cell tumors (NSGCT). Results of the German Prospective multicenter trial (AUO trial 01-94). J Clin Oncol (2006 ASCO Annual meeting proceedings) 24:4512
11. Polverini PJ, Novak RF (1986) Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantrene. Biochem Biophys Res Commun 140:901-907
12. Baguley BC, Holdaway KM, Thomsen LL et al (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism. Eur J Cancer 27:482-487
13. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436
14. Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045-1047
15. Bailar JC 3rd, Gornik HL (1997) Cancer undefeated. N Engl J Med 336:1569-1574
16. Browder T, Butterfield CE, Kraling BM et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886
17. Klement G, Baruchel S, Rak J et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-24
18. Vacca A, Iurlaro M, Ribatti D et al (1999) Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94:4143-4155
19. Klement G, Huang P, Mayer B et al (2002) Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR- 2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 8:221-232
20. Bertolini F, Paul S, Mancuso P et al (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342-4346
21. Man S, Bocci G, Francia G et al (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62:2731-2735
22. Nuyts RM, Pels E, Greve EL (1992) The effects of 5-fluorouracil and mitomycin C on the corneal endothelium. Curr Eye Res 11:565-570
23. Kachel DL, Martin WJ 2nd (1994) Cyclophosphamide- induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther 268:42-46
24. Hoorn CM, Wagner JG, Petry TW, Roth RA (1995) Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol Appl Pharmacol 130:87-94
25. Steiner R (1992) Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay. EXS 61:449-454
26. Belotti D, Vergani V, Drudis T et al (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843-1849
27. Lau DH, Xue L, Young LJ et al (1999) Paclitaxel (Taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 14:31-36
28. Presta M, Rusnati M, Belleri M et al (1999) Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. Cancer Res 59:2417-2424
29. Yonekura K, Basaki Y, Chikahisa L et al (1999) UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 5:2185-2191
30. O'Leary JJ, Shapiro RL, Ren CJ et al (1999) Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 5:181-187
31. Iyer S, Chaplin DJ, Rosenthal DS et al (1998) Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 58:4510-4514
32. Chaplin DJ, Pettit GR, Hill SA (1999) Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res 19:189-195
33. Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62:6938-6943
34. Hirata S, Matsubara T, Saura R et al (1989) Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by lowdose methotrexate. Arthritis Rheum 32:1065-1073
35. Wang J, Lou P, Lesniewski R, Henkin J (2003) Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14:13-19
36. Grant DS, Williams TL, Zahaczewsky M, Dicker AP (2003) Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 104:121-129
37. Chen H, Herndon ME, Lawler J (2000) The cell biology of thrombospondin-1. Matrix Biol 19: 597-614
38. de Fraipont F, Nicholson AC, Feige JJ, Van Meir EG (2001) Thrombospondins and tumor angiogenesis. Trends Mol Med 7:401-407
39. Lawler J (2002) Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6:1-12
40. Guo N, Krutzsch HC, Inman JK, Roberts DD (1997) Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57:1735-1742
41. Dawson DW, Pearce SF, Zhong R et al (1997) CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138:707-717
42. Kato H, Ichinose Y, Ohta M et al (2004) A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713-1721
43. Colleoni M, Rocca A, Sandri MT et al (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13:73-80
44. Orlando L, Cardillo A, Ghisini R et al (2006) Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 6:225
45. Glode LM, Barqawi A, Crighton F et al (2003) Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 98:1643-1648
46. Vogt T, Hafner C, Bross K et al (2003) Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 98:2251-2256
47. Spieth K, Kaufmann R, Gille J (2003) Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: A pilot study. Cancer Chemother Pharmacol 52:377-382
48. Bottini A, Generali D, Brizzi MP et al (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24:3623-3628
49. Correale P, Cerretani D, Remondo C et al (2006) A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep 16:133-140
50. Pietras K, Hanahan D (2005) A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23: 939-952
51. Shaked Y, Emmenegger U, Man S et al (2005) Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106:3058-3061
52. Munoz R, Man S, Shaked Y et al (2006) Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66:3386-3391
53. Takahashi Y, Mai M, Sawabu N, Nishioka K (2005) A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer. Pancreas 30:206- 210